Results 121 to 130 of about 110,016 (261)

Retrohepatic Vena Cava Encirclement, as Surrogate of Extensive Liver Manipulation During Caval Sparing Hepatectomy, Is a Risk Factor for Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma

open access: yesJournal of Surgical Oncology, EarlyView.
ABSTRACT Introduction In liver transplantation (LT) with a caval sparing (CS) approach, the presence of complete encirclement of inferior vena cava (IVC‐E) by hypertrophic segment 1 increases the technical complexity of hepatectomy. Thus, in LT for hepatocellular carcinoma (HCC), It may be suspected that the resulting greater liver manipulation and ...
Riccardo Pravisani   +9 more
wiley   +1 more source

Rethinking Age Limits in Oncoplastic Breast Surgery: Long‐Term Outcomes of Oncoplastic Surgery in Elderly Patients

open access: yesJournal of Surgical Oncology, EarlyView.
ABSTRACT Background and Methods Although OBS is a well‐established approach, evidence regarding its long‐term safety and outcomes in older women remains limited. We performed a retrospective analysis to identify patients ≥ 60 years who underwent OBS for breast cancer between 2001 and 2014.
Francesca De Lorenzi   +9 more
wiley   +1 more source

Pleomorphic Ductal Carcinoma of Breast: Two Cases and Review Literature

open access: yesActa Medica Iranica, 2019
We report two cases of pleomorphic breast carcinoma, a rare variant of high-grade invasive ductal breast carcinoma of no special type, which is a combination of pleomorphic and bizarre giant cells in an adenocarcinoma background.
Mansour Moghimi   +3 more
doaj  

Treatment Response and Oncologic Outcomes Following Neoadjuvant Chemotherapy Switch in Localized Pancreatic Ductal Adenocarcinoma

open access: yesJournal of Surgical Oncology, EarlyView.
ABSTRACT Background and Objectives Many patients undergoing neoadjuvant therapy for localized pancreatic ductal adenocarcinoma (PDAC) experience treatment intolerance or disease progression during initial therapy. Although chemotherapy switch is increasingly utilized, response rates and oncologic outcomes remain poorly defined.
Galen C. Gist   +14 more
wiley   +1 more source

A Case of Ductal Carcinoma In Situ of the Breast [PDF]

open access: yesJapanese Journal of Clinical Oncology, 2008
Miwa, Yoshida, Takayuki, Kinoshita
openaire   +2 more sources

Development of a Nomogram‐Based Clinical Estimation Model for Pathological Upstaging in Patients With Preoperative Ductal Carcinoma In Situ

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Preoperative diagnosis of ductal carcinoma in situ (DCIS) may be followed by pathological upstaging to invasive ductal carcinoma (IDC) upon surgical excision, a discrepancy that significantly impacts surgical planning and decisions regarding sentinel lymph node biopsy (SLNB).
Yu‐Hua Chen   +5 more
wiley   +1 more source

Pretreatment Prediction of Tumor Recurrence in Breast Cancer After Neoadjuvant Systemic Therapy Using Machine Learning With Clinical and CT Radiomics Features

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT This study aimed to develop machine learning models for predicting tumor recurrence in breast cancer before neoadjuvant systemic therapy (NST) by integrating clinical and radiomic features derived from pretreatment computed tomography (CT).
Huei‐Yi Tsai   +6 more
wiley   +1 more source

Core Needle Biopsy in the Diagnosis of Major Salivary Gland Tumors

open access: yesThe Laryngoscope, EarlyView.
In this retrospective study, the diagnostic utility and reliability of CNB were evaluated in 247 CNB samples obtained from 217 patients with major salivary gland lesions, including both surgically confirmed lesions and conservatively managed cases. High diagnostic accuracy was demonstrated for CNB in the evaluation of major salivary gland lesions, and ...
Mira Naukkarinen   +6 more
wiley   +1 more source

Data‐Independent Acquisition Mass Spectrometry in Tumor Classification and Cancer Biomarker Research

open access: yesMass Spectrometry Reviews, EarlyView.
Abstract Cancer treatment is far from optimal also because current classification systems do not reflect the complex molecular status of the tumor and its phenotype in sufficient detail. To construct molecular tumor classifiers, omics tools provide complex molecular data reflecting many aspects from genotype to phenotype.
Jan Simonik   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy